APVO451
Solid Tumors (Nectin-4+)
DiscoveryActive
Key Facts
About Aptevo Therapeutics
Aptevo Therapeutics is a Seattle-based biotech focused on developing next-generation, multi-specific antibody therapies for cancer. The company's core strategy is its proprietary protein engineering platform, which enables the rational design of T-cell engagers and co-stimulatory molecules with tunable properties to potentially overcome limitations of current immunotherapies. Its most advanced asset, mipletamig (APVO436), is a CD3xCD123 bispecific in Phase 1/2 development for acute myeloid leukemia (AML). Operating as a lean, publicly-traded entity, Aptevo aims to advance its broad, early-stage pipeline through clinical validation and strategic partnerships.
View full company profileTherapeutic Areas
Other Solid Tumors (Nectin-4+) Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO455 | Aptevo Therapeutics | Preclinical |